Determining Immune Components of DBA/2J Glaucoma
Principal Investigator
Saidas Nair, PhD
University of California, San Francisco
San Francisco, CA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
July 01, 2007 - June 30, 2009
Grant ID
G2007028
Acknowledgement
Goals
These investigators propose to use genetically altered DBA/2J mice that are devoid of a subset of immune cells that mediate inflammatory responses. They will determine if the mice develop high IOP and glaucoma in the absence of these cells. Also, they will test if a specific DBA/2J gene predisposes to the inflammation and thereby confers susceptibility to IOP elevation.
Grantee institution at the time of this grant: The Jackson Laboratory
Summary
Harmfully high intraocular pressure (IOP) is a major risk factor for glaucoma. Pigment dispersion syndrome (PDS) is a common condition that deposits abnormally liberated iris pigment into the pathway that drains the ocular fluid from the eye. In some cases, the deposited pigment harms the drain resulting in high IOP and glaucoma. Not all PDS progresses to high IOP and glaucoma suggesting that the pigment itself is not sufficient to induce high IOP. DBA/2J mice have pigment dispersion, mild intraocular inflammation and develop high IOP. We hypothesize that the pigment dispersion and inflammation cooperate to induce the high IOP in these mice. To test this hypothesis, we will use genetically altered DBA/2J mice that are devoid of a subset of immune cells that mediate inflammatory responses. We will determine if the mice develop high IOP and glaucoma in the absence of these cells. Also, we will test if a specific DBA/2J gene predisposes to the inflammation and thereby confers susceptibility to IOP elevation. Our studies may suggest new therapies to prevent progression from PDS to glaucoma by reducing inflammatory responses.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute